09/04/2020
Label.BlogRelatedPostsText
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA set to expand Specialty portfolio with positive CHMP opinion on Kinpeygo orphan medicine for IgAN kidney disease
STADA has taken a significant step towards expanding its Specialty portfolio
Corona Survey
Insights into how people in four major European countries are feeling about healthcare issues amid the COVID-19 crises.